Form 4: Vertex Pharmaceuticals Executive Ourania Tatsis Reports Stock Transactions
SEC Form 4 Filing
Ourania Tatsis, EVP, Chief Regulatory & Quality Officer at Vertex Pharmaceuticals, reports the disposition and acquisition of company stock.
Summary
- Ourania Tatsis, an executive at Vertex Pharmaceuticals, reported transactions involving the company's common stock.
- On February 26, 2025, 4,962 shares were disposed of at a price of $479.61.
- On February 27, 2025, 530 shares were disposed of at a price of $475.34.
- Following these transactions, Tatsis directly owns 58,539 shares of Vertex Pharmaceuticals.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing stock transactions. It doesn't inherently convey positive or negative sentiment.
Industry Context
This filing is a routine disclosure of stock transactions by a company executive, which is a common practice among publicly traded companies. It provides transparency into the trading activities of company insiders.
Stakeholder Impact
- The stock transactions by a company executive may be of interest to shareholders.
Key Dates
| Date | Description |
|---|---|
| 02/29/2024 | Date of entry into the Rule 10b5-1 trading plan. |
| 02/26/2025 | Date of disposition of 4,962 shares of common stock. |
| 02/27/2025 | Date of disposition of 530 shares of common stock. |
| 02/28/2025 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.